Technologies

A non-invasive test for detecting colorectal cancer (CRC) measures DNA methylation using a unique panel of gene biomarkers. Designed for cancer screening and diagnosis, the test relies on an assay type known to be stable and can be performed on any bodily fluid that permits extraction and concentration of nucleic acids. This notably includes blood, stool, and urine. This patent-pending technology uses measures of aberrant DNA methylation gene patterns that have been linked to CRC. In a pilot study, the composite biomarker panel demonstrated 100 percent sensitivity and specificity for CRC detection. Because sample analysis can occur in any clinical lab setting, the test has the potential to be incorporated into national cancer screening programs.